Bio­gen piv­ots to sec­ond amy­loid-tar­get­ed Alzheimer's drug with ac­cel­er­at­ed ap­proval fil­ing from part­ner Ei­sai

Al­most ex­act­ly a year ago, Bio­gen CEO Michel Vounatsos boast­ed that the com­pa­ny’s new Alzheimer’s drug, prep­ping for bil­lions in sales fol­low­ing its quick FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER